To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Cingulate's recent SEC filings ...
KANSAS CITY, Kan. and PRINCETON, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug ...
About Attention Deficit/Hyperactivity Disorder (ADHD)ADHD is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The condition is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback